Mendelian randomisation in cardiovascular research: An introduction for clinicians

Heart

Volumn 103, Issue 18, 2017, Pages 1400-1407

  Bennett, Derrick A ^a   Holmes, Michael V ^a,b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKER; DARAPLADIB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE 9;

BODY MASS; CARDIOVASCULAR DISEASE; CAUSALITY; DRUG REPOSITIONING; GENETIC VARIABILITY; HUMAN; ISCHEMIC HEART DISEASE; MENDELIAN RANDOMIZATION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACOGENETICS; PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TELOMERE LENGTH; CARDIOVASCULAR DISEASES; GENETICS; MEDICAL RESEARCH; METABOLISM; PROCEDURES;

BIOMARKERS; BIOMEDICAL RESEARCH; CARDIOVASCULAR DISEASES; HUMANS; MENDELIAN RANDOMIZATION ANALYSIS;

EID: 85026286230     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2016-310605     Document Type: Review

References (52)

1. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20-536 high-risk individuals: a randomised placebocontrolled trial. The Lancet 2002; 360: 7-22.
2. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. The Lancet 2001; 358: 1033-41.
3. Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1459-544.
4. Kassebaum NJ, Arora M, Barber RM, et al. Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1603-58.
5. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996; 312: 1215-8.
6. Banach M, Aronow WS. Blood pressure j-curve: current concepts. Curr Hypertens Rep 2012; 14: 556-66.
7. Wright JT, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103-16.
8. Delgado-Rodríguez M, Llorca J. Bias. J Epidemiol Community Health 2004; 58: 635-41.
9. Rassen JA, Brookhart MA, Glynn RJ, et al. Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. J Clin Epidemiol 2009; 62: 1226-32.
10. Rassen JA, Brookhart MA, Glynn RJ, et al. Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. J Clin Epidemiol 2009; 62: 1233-41.
11. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010; 466: 707-13.
12. Zheng J, Rao DC, Shi G. An update on genome-wide association studies of hypertension. Applied Informatics 2015; 2: 10.
13. Speliotes EK, Willer CJ, Berndt SI, et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet 2010; 42: 937-48.
14. Voight BF, Scott LJ, Steinthorsdottir V, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010; 42: 579-89.
15. Wehby GL, Ohsfeldt RL, Murray JC. 'Mendelian randomization' equals instrumental variable analysis with genetic instruments. Stat Med 2008; 27: 2745-9.
16. Smith GD, Timpson N, Ebrahim S. Strengthening causal inference in cardiovascular epidemiology through Mendelian randomization. Ann Med 2008; 40: 524-41.
17. Katan M, Isoforms AE. Serum cholesterol, and cancer. Lancet 1986; 1: 507-8.
18. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
19. Ference BA, Majeed F, Penumetcha R, et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial mendelian randomization study. J Am Coll Cardiol 2015; 65: 1552-61.
20. Morgan TH, ed. Heredity and sex. New York: Columbia University Press, 1913.
21. Hingorani A, Humphries S. Nature's randomised trials. Lancet 2005; 366: 1906-8.
22. Davey Smith G, Ebrahim S. What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? BMJ 2005; 330: 1076-9.
23. Davey Smith G, Ebrahim S, Lewis S, et al. Genetic epidemiology and public health: hope, hype, and future prospects. Lancet 2005; 366: 1484-98.
24. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for mendelian randomization. Stat Methods: Med Res 2015.
25. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 2014; 23:R89-R98.
26. Martens EP, Pestman WR, de Boer A, et al. Instrumental variables: application and limitations. Epidemiology 2006; 17: 260-7.
27. Lawlor DA, Harbord RM, Sterne JA, et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008; 27: 1133-63.
28. Swerdlow DI, Kuchenbaecker KB, Shah S, et al. Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. Int J Epidemiol 2016; 45: 1600-16.
29. Scheller Madrid A, Rode L, Nordestgaard BG, et al. Short telomere length and ischemic heart disease: observational and genetic studies in 290 022 individuals. Clin Chem 2016; 62: 1140-9.
30. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629.
31. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015; 44: 512-25.
32. Hägg S, Fall T, Ploner A, et al. Adiposity as a cause of cardiovascular disease: a mendelian randomization study. Int J Epidemiol 2015; 44: 578-86.
33. Nelson MR, Tipney H, Painter JL, et al. The support of human genetic evidence for approved drug indications. Nat Genet 2015; 47: 856-60.
34. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375: 1536-44.
35. Chen Z, Chen J, Collins R, et al. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int J Epidemiol 2011; 40: 1652-66.
36. Millwood IY, Bennett DA, Walters RG, et al. Lipoprotein-associated phospholipase A2 loss-of-function variant and risk of vascular diseases in 90,000 Chinese adults. J Am Coll Cardiol 2016; 67: 230-1.
37. O'Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the solid-TIMI 52 randomized clinical trial. JAMA 2014; 312: 1006-15.
38. White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014; 370: 1702-11.
39. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet; 344: 1383-9.
40. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
41. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016; 388: 2532-61.
42. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015; 385: 351-61.
43. Lotta LA, Sharp SJ, Burgess S, et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA 2016; 316: 1383-91.
44. Schmidt AF, Swerdlow DI, Holmes M V, et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol 2017; 5: 97-105.
45. Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med 2016; 375: 2144-53.
46. White J, Swerdlow DI, Preiss D, et al. Association of lipid fractions with risks for coronary artery disease and diabetes. JAMA Cardiol 2016; 1: 692-9.
47. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015; 12: e1001779.
48. Millwood IY, Bennett DA, Walters RG, et al. A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults. Int J Epidemiol 2016; 45: 1588-99.
49. Tardif JC, Rhéaume E, Lemieux Perreault L P, et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet 2015; 8: 372-82.
50. Jansen H, Samani NJ, Schunkert H. Mendelian randomization studies in coronary artery disease. Eur Heart J 2014; 35: 1917-24.
51. Holmes MV, Dale CE, Zuccolo L, et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ 2014; 349:g4164.
52. Asvold BO, Bjorngaard JH, Carslake D, et al. Causal associations of tobacco smoking with cardiovascular risk factors: a Mendelian randomization analysis of the HUNT Study in Norway. Int J Epidemiol 2014; 43: 1458-70.